ADMA Biologics (ADMA) 2024 Cantor Fitzgerald Global Healthcare Conference summary

Business overview and product differentiation

• Manufactures human-derived immunoglobulins, with end-to-end control from plasma collection to finished product, operating ten plasma centers and a large manufacturing plant in Florida.

• Three main products: Nabi-HB (hepatitis B), BIVIGAM (primary immune deficiency), and ASCENIV, a differentiated immunoglobulin for primary immune deficiency using high-titer plasma from select donors.

• ASCENIV leverages patented donor screening and plasma pooling methodologies, resulting in a unique antibody profile that benefits severely immunocompromised patients.

• Intellectual property protection for ASCENIV extends through 2035, with significant know-how and operational expertise required for replication.

• Competitive barriers include multi-year development timelines and regulatory hurdles for potential entrants.

Market trends, demand, and commercial performance

• Post-pandemic, increased medical community engagement and education led to greater awareness and utilization of ASCENIV.

• Real-world evidence and patient outcomes have driven demand, with patients remaining on ASCENIV long-term due to sustained benefits.

• Demand visibility has improved, with defined appropriate use and a clear understanding of production and supply chain cycles.

• ASCENIV now accounts for over 50% of revenue, with a mix shift from BIVIGAM to ASCENIV driving higher margins.

• Commercial success is measured by reduced infections and hospitalizations, improved patient quality of life, and strong payer support for high-need patients.

Financial outlook and growth strategy

• Revenue guidance provided through 2025, with potential for $1.5–$2 billion in annual revenue if capacity is fully dedicated to ASCENIV.

• Yield enhancement initiatives could increase bulk drug output by 20%, with anticipated financial impact from late 2025 or 2026 onward.

• Gross margins for ASCENIV exceed 80%, with corporate gross margins around 50%; yield improvements expected to further boost profitability.

• Balance sheet is strong, with ongoing debt reduction and positive cash generation.

• Management anticipates compounding growth, expanding margins, and operating leverage as ASCENIV becomes a larger share of the product mix.